Monoclonal antibodies targeted against the immune checkpoint molecules CTLA-4 and PD-
1 have recently obtained approval for the treatment of metastatic melanoma and …

Objective To define the clinical characteristics, management, and outcome of neurologic
immune-related adverse events (n-irAEs) of immune checkpoint inhibitors (ICIs). Methods …

COVID-19-associated acute necrotizing myelitis | Neurology Neuroimmunology &
Neuroinflammation Skip to main content Skip to main content AAN.com AAN Publications Author …

Importance Encephalitis is a severe immune-related adverse event secondary to treatment
with immune checkpoint inhibitors (ICIs). The spectrum of ICI-induced encephalitis (ICI-iE) …

Background Treatment with checkpoint inhibitors such as anti-programmed death-1 (anti-PD-
1), anti-PD-ligand 1 (anti-PD-L1), and anti-cytotoxic T-lymphocyte antigen-4 (anti-CTLA-4) …

Summary CTLA‐4 and PD‐1 are potential targets for tumor‐induced downregulation of
lymphocytic immune responses. Immune checkpoint‐modifying monoclonal antibodies …

The use of immune checkpoint inhibitor (ICI) therapy in the treatment of solid organ
malignancies is becoming increasingly common. This has prompted the recognition of a …

Summary CTLA‐4 and PD‐1 play a key role in tumor‐induced downregulation of
lymphocytic immune responses. Immune checkpoint inhibitors have been shown to alter the …

Immunotherapy with checkpoint inhibitors has revolutionized the management of metastatic
melanoma. These checkpoints, namely the cytotoxic T lymphocyte antigen 4 and the …

The next decade in cancer therapy will be marked by the expansion of immunotherapies,
namely immune checkpoint inhibitors. The increasing number and combination of …